Development of MEDI4736, an anti-programmed cell death ligand 1 PD-L1 antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer NSCLCReport as inadecuate




Development of MEDI4736, an anti-programmed cell death ligand 1 PD-L1 antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer NSCLC - Download this document for free, or read online. Document in PDF available to download.

Journal for ImmunoTherapy of Cancer

, 2:P179

First Online: 06 November 2014DOI: 10.1186-2051-1426-2-S3-P179

Cite this article as: Brahmer, J., Balmanoukian, A., Goldberg, S. et al. j. immunotherapy cancer 2014 2Suppl 3: P179. doi:10.1186-2051-1426-2-S3-P179 Download fulltext PDF



Author: Julie Brahmer - Ani Balmanoukian - Sarah Goldberg - Sai-Hong Ou - Andrew Blake-Haskins - Joyson Karakunnel - Paul Stockman

Source: https://link.springer.com/







Related documents